Tesla may have entered the biomedical field based on Elon Musk’s recent responses on Twitter. According to Musk, Tesla has been working with leading clinical state biotechnology company CureVac in Germany. CureVac is developing an mRNA-based vaccine against the C-19 virus, and Tesla seems to be helping.
“In principle, I think synthetic RNA (and DNA) has amazing potential. This basically makes the solution to many diseases a software problem,” replied Elon Musk to a question about his thought on RNA vaccines by @SamTalksTesla. Musk later followed-up his reply, tweeting: “Tesla, as a side project is building RNA microfactories for CureVac & possibly others.”
Biotech company CureVac has been working on an mRNA-based vaccine against the novel coronavirus since early January 2020. Later that month, the CEPI (the Coalition for Epidemic Preparedness Innovations) foundation granted CureVac additional initial funding of up to US$8.3 million to accelerate the development, manufacturing, and clinical tests for its mRNA-based vaccine.
mRNA vaccines are relatively new in the medical world, and most of the information about them comes from research focused on cancer. Traditional vaccines are made out of small and usually inactivated pieces of the disease-causing organisms or the proteins the virus or bacteria produces in the body. The small or inactivated pieces are injected into the body, provoking the immune system to activate and create cells to defend against “intruders.”